The U.S. Food and Drug Administration (FDA) has granted expanded access for the use of an experimental pancreatic cancer drug, daraxonrasib. This means the drug will be available for early access to those who previously received conventional treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). A health care provider must request access to the medication for their patient, according to an FDA statement.

AI summaries can be wrong sometimes—always verify important details using the source article.